Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of drugs that have been extensively investigated for the treatment of hyperglycemia in type 2 diabetes mellitus (T2DM). These drugs reduce hyperglycemia by blocking renal glucose reabsorption, thereby promoting increased renal gluco...

Descripción completa

Detalles Bibliográficos
Autor principal: Kalra, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125111/
https://www.ncbi.nlm.nih.gov/pubmed/27539303
http://dx.doi.org/10.1007/s40119-016-0069-z
_version_ 1782469932300107776
author Kalra, Sanjay
author_facet Kalra, Sanjay
author_sort Kalra, Sanjay
collection PubMed
description Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of drugs that have been extensively investigated for the treatment of hyperglycemia in type 2 diabetes mellitus (T2DM). These drugs reduce hyperglycemia by blocking renal glucose reabsorption, thereby promoting increased renal glucose excretion. Beyond glycemic control, these drugs have other beneficial effects on cardiovascular (CV) risk factors. The present review discusses the potential role of SGLT2 inhibitors in treating CV complications (acute and chronic) associated with T2DM. Funding: AstraZeneca Pharma India Ltd.
format Online
Article
Text
id pubmed-5125111
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-51251112016-12-12 Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review Kalra, Sanjay Cardiol Ther Review Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of drugs that have been extensively investigated for the treatment of hyperglycemia in type 2 diabetes mellitus (T2DM). These drugs reduce hyperglycemia by blocking renal glucose reabsorption, thereby promoting increased renal glucose excretion. Beyond glycemic control, these drugs have other beneficial effects on cardiovascular (CV) risk factors. The present review discusses the potential role of SGLT2 inhibitors in treating CV complications (acute and chronic) associated with T2DM. Funding: AstraZeneca Pharma India Ltd. Springer Healthcare 2016-08-18 2016-12 /pmc/articles/PMC5125111/ /pubmed/27539303 http://dx.doi.org/10.1007/s40119-016-0069-z Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Kalra, Sanjay
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
title Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
title_full Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
title_fullStr Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
title_full_unstemmed Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
title_short Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
title_sort sodium-glucose cotransporter 2 (sglt2) inhibitors and cardiovascular disease: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125111/
https://www.ncbi.nlm.nih.gov/pubmed/27539303
http://dx.doi.org/10.1007/s40119-016-0069-z
work_keys_str_mv AT kalrasanjay sodiumglucosecotransporter2sglt2inhibitorsandcardiovasculardiseaseasystematicreview

Ejemplares similares